MX2020002652A - Esteroides neuroactivos y su método de uso. - Google Patents

Esteroides neuroactivos y su método de uso.

Info

Publication number
MX2020002652A
MX2020002652A MX2020002652A MX2020002652A MX2020002652A MX 2020002652 A MX2020002652 A MX 2020002652A MX 2020002652 A MX2020002652 A MX 2020002652A MX 2020002652 A MX2020002652 A MX 2020002652A MX 2020002652 A MX2020002652 A MX 2020002652A
Authority
MX
Mexico
Prior art keywords
methods
pharmaceutically acceptable
compound
neuroactive steroids
related disorders
Prior art date
Application number
MX2020002652A
Other languages
English (en)
Inventor
Stephen Jay Kanes
Ethan Hoffmann
George Nomikos
Handan Gunduz-Bruce
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2020002652A publication Critical patent/MX2020002652A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención se refiere al Compuesto 1(VER FORMULA) (Compuesto 1) sales farmacéuticamente aceptables, o composiciones farmacéuticamente aceptables del mismo, para el tratamiento de trastornos relacionados con el SNC, por ej. temblor, por ej. temblor esencial; depresión; y trastorno de la ansiedad, y métodos para mejorar la efectividad de la administración del Compuesto 1 para tratar dichos trastornos relacionados con el SNC. La invención también se refiere a métodos para incrementar la biodisponibilidad de un Compuesto 1 o sales farmacéuticamente aceptables, o composiciones farmacéuticamente aceptables del mismo.
MX2020002652A 2017-09-07 2018-09-07 Esteroides neuroactivos y su método de uso. MX2020002652A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555404P 2017-09-07 2017-09-07
US201762595998P 2017-12-07 2017-12-07
PCT/US2018/050012 WO2019051264A1 (en) 2017-09-07 2018-09-07 NEUROACTIVE STEROIDS AND METHODS OF USE

Publications (1)

Publication Number Publication Date
MX2020002652A true MX2020002652A (es) 2020-09-25

Family

ID=63794613

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020002652A MX2020002652A (es) 2017-09-07 2018-09-07 Esteroides neuroactivos y su método de uso.
MX2023009610A MX2023009610A (es) 2017-09-07 2020-03-06 Esteroides neuroactivos, y su metodo de uso.
MX2023009611A MX2023009611A (es) 2017-09-07 2020-03-06 Esteroides neuroactivos, y su metodo de uso.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2023009610A MX2023009610A (es) 2017-09-07 2020-03-06 Esteroides neuroactivos, y su metodo de uso.
MX2023009611A MX2023009611A (es) 2017-09-07 2020-03-06 Esteroides neuroactivos, y su metodo de uso.

Country Status (11)

Country Link
US (2) US20200281943A1 (es)
EP (1) EP3678670A1 (es)
JP (2) JP2020533310A (es)
CN (2) CN111491637A (es)
AU (1) AU2018327357A1 (es)
CA (1) CA3075038A1 (es)
IL (2) IL303250A (es)
MX (3) MX2020002652A (es)
SG (1) SG11202002085YA (es)
TW (2) TW202342058A (es)
WO (1) WO2019051264A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
PL2986624T3 (pl) 2013-04-17 2020-11-16 Sage Therapeutics, Inc. Neuroaktywne steroidy 19-NOR do stosowania w sposobach leczenia
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US9512165B2 (en) 2013-04-17 2016-12-06 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
CA2918735C (en) 2013-07-19 2023-08-01 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3035940B1 (en) 2013-08-23 2018-10-17 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN117024501A (zh) 2014-10-16 2023-11-10 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
NZ769042A (en) 2014-10-16 2023-12-22 Sage Therapeutics Inc Compositions and methods for treating cns disorders
PT3224269T (pt) 2014-11-27 2020-06-01 Sage Therapeutics Inc Composições e métodos para tratamento de distúrbios do snc
SI3250210T1 (sl) 2015-01-26 2021-07-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
WO2016134301A2 (en) 2015-02-20 2016-08-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN109689673B (zh) 2016-07-11 2023-03-14 萨奇治疗股份有限公司 C17、c20和c21取代的神经活性类固醇及其使用方法
AU2017296295B2 (en) 2016-07-11 2022-02-24 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use
JOP20190022B1 (ar) 2016-08-23 2023-03-28 Sage Therapeutics Inc ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري
KR20200096596A (ko) 2017-12-08 2020-08-12 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
CN112533611A (zh) * 2018-06-12 2021-03-19 萨奇治疗股份有限公司 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
CN111454318A (zh) * 2019-01-20 2020-07-28 浙江易众化工有限公司 抗抑郁药物sage-217的晶型及其制备方法
BR112021024033A2 (pt) 2019-05-31 2022-02-08 Sage Therapeutics Inc Esteroides neuroativos e suas composições
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
JP2023504517A (ja) * 2019-12-05 2023-02-03 セージ セラピューティクス， インコーポレイテッド １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法
US20230346801A1 (en) 2020-03-25 2023-11-02 Sage Therapeutics, Inc. Use of agents for treatment of respiratory conditions
AR123018A1 (es) * 2020-07-20 2022-10-26 Sage Therapeutics Inc Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y métodos de uso de este
US20230372364A1 (en) * 2020-10-01 2023-11-23 Jeremy Hill Method of treating gaba mediated disorders
EP4199723A1 (en) * 2020-10-01 2023-06-28 Eliem Therapeutics (UK) Ltd Methods of treating fibromyalgia with neuroactive steroids
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090131383A1 (en) * 2005-06-09 2009-05-21 Woodward Richard M Pharmaceutical compositions of a neuroactive steriod and methods of use thereof
US8575375B2 (en) * 2007-06-15 2013-11-05 Research Triangle Institute Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
US9512165B2 (en) * 2013-04-17 2016-12-06 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
JOP20170059B1 (ar) * 2016-03-08 2021-08-17 Sage Therapeutics Inc ستيرويدات وتركيبات نشطة عصبيًا واستخداماتها
JOP20190022B1 (ar) * 2016-08-23 2023-03-28 Sage Therapeutics Inc ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري

Also Published As

Publication number Publication date
IL303250A (en) 2023-07-01
US20230310459A1 (en) 2023-10-05
SG11202002085YA (en) 2020-04-29
CN117771252A (zh) 2024-03-29
MX2023009610A (es) 2023-08-24
EP3678670A1 (en) 2020-07-15
US20200281943A1 (en) 2020-09-10
IL273099A (en) 2020-04-30
CA3075038A1 (en) 2019-03-14
JP2023033543A (ja) 2023-03-10
CN111491637A (zh) 2020-08-04
AU2018327357A1 (en) 2020-03-26
WO2019051264A1 (en) 2019-03-14
JP2020533310A (ja) 2020-11-19
TW202342058A (zh) 2023-11-01
TW201919641A (zh) 2019-06-01
MX2023009611A (es) 2023-08-24

Similar Documents

Publication Publication Date Title
MX2023009610A (es) Esteroides neuroactivos, y su metodo de uso.
MX2021004492A (es) Composiciones para el tratamiento de trastornos del snc.
PH12018500087A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
MX2023002006A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MX2022016276A (es) Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
MX2023005098A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
MX2020010151A (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn.
MX2017011951A (es) Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso.
MX2019008626A (es) Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl).
MX2015010829A (es) Compuestos terapeuticos y sus usos.
PH12019500196A1 (en) Compounds and compositions and uses thereof
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
SG10201806809QA (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
MX2017017171A (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
SG10201907289VA (en) Monomethylfumarate prodrug compositions
MX2019015371A (es) Derivados de dihidro-pirrolo-piridina.
PH12021550671A1 (en) Prodrugs of cgrp antagonists
PH12017501736A1 (en) Indole derivatives